Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020

Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar

Mwinyi Msellem, Ulrika Morris, Aungpaing Soe, Faiza B. Abbas, Abdul-Wahid Ali, Rory Barnes, Paolo Frumento, Abdullah S. Ali, Andreas Mårtensson, and Anders BjörkmanComments to Author 
Author affiliations: Mnazi Mmoja Hospital, Zanzibar, Tanzania (M. Msellem); Karolinska Institutet, Stockholm, Sweden (U. Morris, A. Soe, R. Barnes, P. Frumento, A. Bjorkman); Zanzibar Malaria Elimination Programme, Zanzibar, Tanzania (F.B. Abbas, A.-W. Ali, A.S. Ali); Uppsala University, Uppsala, Sweden (A. Mårtensson)

Main Article

Table 5

Parasite clearance determined by qPCR after treatment with ASAQ and single, low-dose primaquine, Zanzibar, 2017*

Day after treatment Parasite positivity by PCR, no.; % (95% CI) qPCR-determined geometric mean parasite density/μL (range)
Day 3 90; 63 (55–71) 2 (<1−796)
Day 7 42; 30 (22–37) <1 (<1−18)
Day 28 9; 6 (2–10) 1 (<1−58)

*ASAQ, artesunate/amodiaquine; qPCR, quantitative PCR.

Main Article

Page created: May 26, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.